UroGen Pharma Ltd. (URGN)
NASDAQ: URGN
· Real-Time Price · USD
14.35
2.32 (19.29%)
At close: Jun 16, 2025, 3:59 PM
14.00
-2.44%
After-hours: Jun 16, 2025, 07:59 PM EDT
19.29% (1D)
| Bid | 14 |
| Market Cap | 661.64M |
| Revenue (ttm) | 91.87M |
| Net Income (ttm) | -138.43M |
| EPS (ttm) | -3.01 |
| PE Ratio (ttm) | -4.77 |
| Forward PE | -8.5 |
| Analyst | Buy |
| Ask | 14.44 |
| Volume | 8,281,250 |
| Avg. Volume (20D) | 2,384,285 |
| Open | 12.93 |
| Previous Close | 12.03 |
| Day's Range | 12.62 - 14.69 |
| 52-Week Range | 3.42 - 19.01 |
| Beta | 0.40 |
About URGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol URGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for URGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 days ago
+8.57%
UroGen Pharma shares are trading higher after Gugg...
Unlock content with
Pro Subscription
4 days ago
+51.78%
UroGen Pharma shares are trading higher after the FDA approved ZUSDURI for intravesical solution a the first and only medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
